🌟 Meet this week's #TrailblazerThursday spotlight: Ashley M. Fuller, PhD postdoctoral scholar, visionary, and founder🚀 For inquiries about the BEE program, please reach out to Farnaz B. or Bianca Scimemi The BEE Program is generously supported and made possible by the WoodNext Foundation, a donor advised fund sponsored by the Greater Houston Community Foundation. Let's ignite innovation and entrepreneurship together! 💡🚀 #TrailblazerThursday #WomenFounder #Entrepreneurship #Innovation #CancerResearch #StartUps #HealthTech #HealthEquity
About us
SyzOnc is developing tumor microenvironment modulators for cancer patients using a tech-enabled, systems-level approach.
- Website
-
www.syzonc.com
External link for SyzOnc
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Philadelphia, PA
- Type
- Partnership
- Founded
- 2023
Locations
-
Primary
Get directions
Philadelphia, PA, US
Employees at SyzOnc
-
Anne Carpenter
Institute Scientist, Imaging Platform Senior Director, Broad Institute of Harvard and MIT
-
Karin Eisinger
CEO and Co-Founder, SyzOnc LLC
-
Ying Liu
Oncology researcher | Target discovery and drug development
-
Srijit Seal
AFHEA, AMRSC, FCPS, MPhil (Cantab) | Research Associate, Broad Institute of MIT and Harvard | PhD Student in Chemistry, University of Cambridge |…
Updates
-
July is Sarcoma Awareness Month. Sarcomas are understudied and patients lack targeted therapeutics. SyzOnc is committed to improving outcomes for sarcoma patients and is proud to partner with the Sarcoma Foundation of America to serve this community. Learn more here! https://lnkd.in/eeE5f8d
-
SyzOnc is pleased to announce the publication of our landmark study highlighting the critical role of extracellular matrix proteins in regulating the immune microenvironment in solid tumors. https://lnkd.in/effBY8rf
Oncogene-induced matrix reorganization controls CD8 + T cell function in the soft-tissue sarcoma microenvironment
jci.org
-
SyzOnc is pleased to announce that co-founder Karin Eisinger, PhD, has taken the helm as SyzOnc’s full time CEO and co-founder Ashley M. Fuller, PhD, has stepped into the role of CSO. We are grateful to our inaugural CEO Tim Considine, JD for taking SyzOnc to the next level in its early days. Tim will remain on the team in an advisory capacity. We look forward to continuing our work together to build a better future for solid tumor patients.
-
SyzOnc's new website is live! Come visit us at www.syzonc.com. Many thanks to the team at OPTIO - Strategic Storytelling for creating this beautiful site for us.
Home
syzonc.com
-
We're excited to announce that SyzOnc was awarded the MIT-Royalty Pharma pitch competition grand prize! Our sincere thanks to all the mentors and organizers who made this program possible, and congratulations to all of the professors in our cohort! They're all doing brilliant work to make the world a better place :)
Institute Scientist, Imaging Platform Senior Director, Broad Institute of Harvard and MIT
Wow! I'm thrilled that our new company SyzOnc was awarded the Grand Prize in the MIT-Royalty Pharma competition! This cohort of 12 MIT professors represents the best of what science can be when leaders are passionate about making a positive impact on the world. Brilliant ideas and brilliantly executed. If you have a spare few million, I highly recommend investing in this group because you'd have a hard time finding a better-vetted set of startups 😀 . Huge thank you to Sangeeta Bhatia, Macauley Kenney, Kit Hickey, Bill Aulet and all the mentors who contributed to this program that helped launch us all! 🚀
-
-
Very excited at this next stage of growth for the company. Stay tuned for more updates in the weeks ahead.
SyzOnc is thrilled to announce that we’ve opened our doors at B₊labs in Philadelphia. We’re ready to change the face of oncology with our first-in-class human-first, systems-level solution for cancer therapeutics discovery!
-
SyzOnc is thrilled to announce that we’ve opened our doors at B₊labs in Philadelphia. We’re ready to change the face of oncology with our first-in-class human-first, systems-level solution for cancer therapeutics discovery!